Working on nasal vaccine as booster: Bharat Biotech

Bharat Biotech chief and the developer of India’s first indigenously made Covid 19 vaccine, Covaxin, Krishna Ella on Wednesday said six months after the second dose was the best time for a booster adding that the company was working to see if their under development nasal vaccine could serve as a booster as it would be easy to scale up. Ella said negativity and politics over Covaxin which Prime Minister Narendra Modi was the first to take “hurt the product and delayed its WHO emergency use listing approval.”

“When the PM took the vaccine it was called a BJP vaccine. People’s negative projections of Covaxin hurt the product. Politicians should take up different battles, not on the front of science,” Ella said at a television channel’s event today.

Noting that he was happy India was the fourth country worldwide to manufacture a Covid vaccine, Ella said, “Negative perceptions about Covaxin delayed approvals and publication. But I am happy we finally won the game. Negativity also put WHO in an awkward position. WHO wanted to review Covaxin much more extensively. Covaxin was the only shot to go through so much WHO scrutiny.” Ella said although a million pregnant Indian women had received Covaxin and its safety among them is proven, the WHO had sought results of Covaxin safety among pregnant women in a clinical trial mode. The WHO is yet to approve Covaxin for pregnant women.

“We will do the science, although the highest number of pregnant women worldwide has been vaccinated in India and a million of them are on Covaxin with proven safety,” he said.

Be the first to comment

The Indian Panorama - Best Indian American Newspaper in New York & Dallas - Comments